Ionis Pharmaceuticals Inc (OQ:IONS)
Business Focus: Biotechnology & Medical Research
May 16, 2024 07:30 am ET
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucleotide (ASO) for amyotrophic lateral sclerosis (ALS) based on...
May 16, 2024 07:30 am ET
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire studyBiogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive, fatal neurodegenerative conditionCARLSBAD, Calif. and CAMBRIDGE, Mass., May 16, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Biogen Inc. (Nasdaq: BIIB) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucle
May 16, 2024 07:00 am ET
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patientsION582 was safe and well tolerated at all dose levelsIonis plans to move ION582 into pivotal trial Detailed ION582 data to be presented at upcoming medical meetingCARLSBAD, Calif., May 16, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline data from the HALOS Phase 1/2a open-label study of ION582 in Angelman syndrome. ION582 was safe and well tolerated in the study and showed encouraging and consistent benefits in individuals living with An
May 15, 2024 07:05 am ET
Ionis to host 2024 virtual Annual Meeting of Stockholders
CARLSBAD, Calif., May 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 6, 2024.
May 07, 2024 07:00 am ET
Ionis reports first quarter 2024 financial results
WAINUATM launch on track; EU and Canada approval decisions expected this year
Apr 25, 2024 07:00 am ET
Ionis Publishes 2023 Corporate Responsibility Report
Established new corporate responsibility strategic pillars and actionable goals Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring a steady cadence of important new medicines to people with serious diseasesCARLSBAD, Calif., April 25, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today published its 2023 Corporate Responsibility Report: Action for a Healthier Future. The report details Ionis' relentless passion to create better futures for people touched by serious disease as well as other stakeholders. In
Apr 23, 2024 07:05 am ET
Ionis to hold first quarter 2024 financial results webcast
Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern Time
Apr 07, 2024 09:48 am ET
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
– Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events –
Apr 01, 2024 07:05 am ET
Ionis to present at upcoming investor conferences
CARLSBAD, Calif., April 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
Mar 28, 2024 07:05 am ET
Ionis to hold olezarsen Phase 3 data webcast
Webcast scheduled for Monday, April 8 at 10:00 a.m. Eastern Time
Mar 25, 2024 08:18 am ET
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
– First presentation of pivotal results showing significant reduction in triglycerides and substantial reduction in acute pancreatitis events in patients with rare, life-threatening disease, for which there are no approved treatment options in U.S. –
Mar 06, 2024 07:30 am ET
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
Biogen Inc. (Nasdaq: BIIB) announced interim 6-month biomarker data from the initial 29 participants in the open-label RESPOND study.* The Phase 4 study evaluates clinical outcomes and safety following treatment with SPINRAZA over a 2-year period...
Feb 21, 2024 06:00 am ET
Ionis reports fourth quarter and full year 2023 financial results
WAINUA™ approved with launch underway; on track for EU and Canada approval decisions this year
Feb 15, 2024 06:00 am ET
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
CARLSBAD, Calif., Feb. 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the investigational medicine olezarsen for the treatment of familial chylomicronemia syndrome (FCS), a rare, genetic disease characterized by extremely elevated triglyceride levels and recurrent acute pancreatitis (AP). The FDA grants Orphan Drug designation to therapies intended for treatment, prevention or diagnosis of a rare disease or condition that affects fewer than 200,000 people in the U.S. a
Feb 08, 2024 06:00 am ET
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
CARLSBAD, Calif., Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis and AstraZeneca's eplontersen, an investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults. The FDA grants development programs Fast Track designation to facilitate the development and expedite the review of drugs that demonstrate the potential to treat serious conditions and fill an unmet medical need.
Feb 07, 2024 06:05 am ET
Ionis to hold fourth quarter and full year 2023 financial results webcast
Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern Time
Jan 22, 2024 06:00 am ET
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Donidalorsen met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks Donidalorsen demonstrated a favorable safety and tolerability profileIonis is preparing to submit a New Drug Application with U.S. FDA Data to be presented at an upcoming medical congressCARLSBAD, Calif., Jan. 22, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results for the Phase 3 OASIS-HAE study of donidalorsen in people with hereditary angioedema (HAE). The trial m
Jan 08, 2024 08:00 am ET
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition...
Jan 08, 2024 06:03 am ET
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
– Numerous value-driving commercial, regulatory and pipeline milestones anticipated –
Dec 21, 2023 05:55 pm ET
WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
U.S. FDA approval based on Phase 3 NEURO-TTRansform results showing WAINUA demonstrated consistent and sustained benefit halting neuropathy disease progression and improving neuropathy impairment and quality of life Additional regulatory reviews for WAINUA underway in rest of world WAINUA will be available in the U.S. in January 2024CARLSBAD, Calif., Dec. 21, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved Ionis and AstraZeneca's WAINUA™ (eplontersen) for the treatment of the polyneuropathy of hered
Dec 20, 2023 06:05 am ET
Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif., Dec. 20, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT on Wednesday, January 10, 2024.
Dec 18, 2023 03:01 pm ET
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
Otsuka to leverage strong commercial infrastructure and rare disease experience to reach European HAE patientsIonis plans to independently bring donidalorsen to U.S. patients if approvedDonidalorsen Phase 3 results expected in the first half of 2024CARLSBAD, Calif., Dec. 18, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedem
Dec 14, 2023 03:05 pm ET
Ionis announces the appointment of Michael Yang to Board of Directors
CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10.
Nov 16, 2023 08:00 am ET
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition...
Nov 11, 2023 10:30 am ET
Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
Part 1 of HALOS trial evaluating ION582 has completed enrollment with results expected in mid-2024ION582 has been generally well tolerated at all dose levels, and participants are continuing to Part 2, the long-term extension portion of the studyEncouraging EEG and clinical observations support continued developmentMIAMI, Nov. 11, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment and positive preliminary findings from Part 1 of the ongoing HALOS Phase 1/2a study of ION582 (BIIB121) in Angelman syndrome. ION582 was generally well tole
Nov 09, 2023 11:42 am ET
Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema
Continued treatment over two years with donidalorsen demonstrated sustained reduction in hereditary angioedema attacks and improved quality of lifeDonidalorsen recently received orphan drug designation in the U.S.Topline Phase 3 results expected in H1 2024CARLSBAD, Calif., Nov. 9, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from an ongoing Phase 2 open-label extension (OLE) study evaluating the safety and efficacy of its investigational prophylactic medicine, donidalorsen, in patients with hereditary angioedema (HAE), a rare and life-threa
Nov 03, 2023 07:05 am ET
Ionis to present at upcoming investor conferences
CARLSBAD, Calif., Nov. 3, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
Nov 02, 2023 07:00 am ET
Ionis reports third quarter 2023 financial results
Olezarsen Phase 3 data showed significant triglyceride lowering, substantial reductions in acute pancreatitis attacks and favorable safety and tolerability in patients with FCS; on track for regulatory filings in early 2024
Oct 19, 2023 07:05 am ET
Ionis to hold third quarter 2023 financial results webcast
Webcast scheduled for Thursday, November 2 at 11:30 a.m. Eastern Time
Oct 04, 2023 07:00 am ET
Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization
With experienced commercial team in place, Ionis poised to independently bring steady cadence of potentially transformational RNA-targeted medicines to patients beginning in 2024Plan to add four new wholly owned neurology medicines to clinical pipeline by end of 2024Innovative technology advances unlocking new opportunities in neurology and cardiology as well as in new therapeutic areas With multiple launches anticipated over the coming years, Ionis positioned for next-level value creation driven by significant revenue growth and positive cash flowIonis to webcast Innovation Day today at 8:0
Oct 02, 2023 01:17 pm ET
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition...
Sep 28, 2023 12:02 pm ET
Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit
Publication of NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen halted disease progression and continuously improved quality of life at 35-, 66- and 85-week analysesData demonstrates consistent and sustained benefit on all co-primary and secondary endpointsCARLSBAD, Calif., Sept. 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that The Journal of the American Medical Association (JAMA) published positive results from the Phase 3 NEURO-TTRansform study of eplontersen, an investiga
Sep 27, 2023 07:00 am ET
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease
Roche gains exclusive worldwide rights to develop, manufacture and commercialize the investigational medicines discovered by IonisIonis to receive a $60 million upfront paymentCARLSBAD, Calif., Sept. 27, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered an agreement with Roche for two undisclosed early-stage programs for RNA-targeting investigational medicines for the treatment of Alzheimer's disease (AD) and Huntington's disease (HD). Roche gains exclusive worldwide rights and will be responsible for clinical development, manufacturing, and
Sep 26, 2023 07:00 am ET
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placeboFirst study to show an absolute reduction in acute pancreatitis in FCS patients, with olezarsen 80 mg monthly dose reducing events by 100 percent Olezarsen demonstrated a favorable safety and tolerability profileIonis plans to file a New Drug Application with U.S. FDA in preparation for first potential independent launchPhase 3 studies continue evaluating olezarsen in broader patient population with severe hypertriglyceridemia (SHTG) Ionis to host webcast today at 11 a.m. ETCARL
Sep 12, 2023 07:05 am ET
Ionis to host investor and analyst day event
Ionis Innovation Day: Discovering, Developing and Delivering Transformational MedicinesPresentations by key members of Ionis leadership and notable KOLsCARLSBAD, Calif., Sept. 12, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host an investor and analyst day on Wednesday, October 4. The event will take place at the Westin New York Grand Central from 8:00 a.m. to 3:00 p.m. Eastern Time and will also be webcast. The agenda will include presentations by members of the Ionis management team and the following notable key opinion leaders:
Jul 31, 2023 07:05 am ET
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy
CARDIO-TTRansform is the largest, most comprehensive ATTR-CM study with more than 1,400 patients enrolledEplontersen is currently under U.S. FDA review for ATTRv-polyneuropathy, with ATTR-CM representing a second, larger potential patient populationCARLSBAD, Calif., July 31, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment in the Phase 3 CARDIO-TTRansform cardiovascular outcomes study of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a large and growing patient population at risk of life-threat
Jul 28, 2023 07:05 am ET
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America
Companies jointly developing and commercializing eplontersen in the U.S. AstraZeneca adds Latin America as part of its exclusive rights for rest of worldCARLSBAD, Calif., July 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it has expanded its existing collaboration with AstraZeneca to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin America. Ionis previously granted AstraZeneca exclusive rights to commercialize eplontersen in all other countries outside the U.S. Ionis and AstraZeneca will continue to jointly develop and comme
Jul 26, 2023 07:05 am ET
Ionis to hold second quarter 2023 financial results webcast
Webcast scheduled for Wednesday, August 9 at 11:30 a.m. Eastern Time
Jul 10, 2023 07:05 am ET
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks
Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 weeksData further strengthen eplontersen's differentiated profile, positioning it to be an important potential treatment for patients with ATTRv-PNCARLSBAD, Calif., July 10, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced positive topline, 85-week data from the Phase 3 NEURO-TTRansform study in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). Ionis and AstraZeneca's eplontersen continued
Jul 05, 2023 07:05 am ET
Ionis to present at upcoming investor conference
CARLSBAD, Calif., July 5, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at TD Cowen's 2nd Annual RNA Therapeutics Summit on Monday, July 10, 2023.
Jun 30, 2023 04:08 pm ET
New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy
Interim results from RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec) CARLSBAD, Calif., June 30, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA® (nusinersen) in infants and toddlers living with spinal muscular atrophy (SMA). Interim results from the RESPOND study showed improved motor function in most participants treated with SPINRAZA following treatment with Zolgensma® (onasemnogene abeparvovec)
Jun 30, 2023 04:06 pm ET
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
Biogen Inc. (Nasdaq: BIIB) announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community. The data were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA this...
Jun 08, 2023 01:09 am ET
Ionis prices private placement of convertible senior notes
CARLSBAD, Calif., June 7, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today the pricing of $500.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 (the "notes") in a private placement (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Ionis also granted the initial purchasers of the notes an option to purchase, within the 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $75.0 million a
Jun 06, 2023 04:01 pm ET
Ionis announces proposed private placement of convertible notes
CARLSBAD, Calif., June 6, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 (the "notes") in a private placement (the "offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Ionis also intends to grant the initial purchasers of the notes an option to purchase, within the 13-day period beginning on, and including, the first date on w
Jun 01, 2023 07:05 am ET
Ionis announces positive donidalorsen late-stage clinical progress in HAE
Two-year treatment with donidalorsen in the Phase 2 open label study resulted in consistent, sustained protection from HAE attacksCompleted enrollment in the Phase 3 OASIS-HAE studyTopline Phase 3 results expected in H1 2024CARLSBAD, Calif., June 1, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive clinical progress with donidalorsen, its late-stage investigational prophylactic therapy for hereditary angioedema (HAE). Topline two-year open-label extension (OLE) results continue to demonstrate consistent efficacy and safety, with an overall sustained mea
May 10, 2023 07:05 am ET
Ionis to host 2023 virtual Annual Meeting of Stockholders
CARLSBAD, Calif., May 10, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2023 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 1, 2023.
May 09, 2023 07:05 am ET
Ionis to present at upcoming investor conferences
CARLSBAD, Calif., May 9, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
May 03, 2023 07:00 am ET
Ionis reports first quarter 2023 financial results
QALSODY approved for SOD1-ALS; MAA under review in EU
Apr 25, 2023 07:10 pm ET
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
Accelerated approval marks a scientific advancement in treatment of superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS)Approval based on reduction of neurofilament, a biomarker associated with neuronal damage in ALS QALSODY joins SPINRAZA® as Ionis-discovered medicine approved for treatment of a rare and fatal neurodegenerative diseaseCARLSBAD, Calif., April 25, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner Biogen has received U.S. Food and Drug Administration (FDA) approval of QALSODY™ (tofersen) 100 mg/15mL injection for the
Apr 24, 2023 07:00 am ET
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
NEURO-TTRansform study met all co-primary and secondary endpointsPositive results to be presented today at AAN 2023 demonstrate eplontersen efficacy, safety and administration profile may provide an important new treatment option in this fatal disease with significant unmet needIonis to host webcast on Tuesday, April 25 at 1 p.m. ETCARLSBAD, Calif., April 24, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Phase 3 NEURO-TTRansform study for AstraZeneca and Ionis' eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (AT
Apr 20, 2023 07:05 am ET
Ionis to hold first quarter 2023 financial results webcast
Webcast scheduled for Wednesday, May 3 at 11:30 a.m. Eastern Time
Mar 29, 2023 08:45 am ET
New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease
Phase 1b study showed dose-dependent and sustained reduction of tau protein in cerebrospinal fluid through open-label long-term extension (LTE)IONIS-MAPTRx reduced aggregated tau pathology across all brain composites assessed starting as early as week 25 through week 100CARLSBAD, Calif., March 29, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported that its partner Biogen presented new Phase 1b clinical data showing that IONIS-MAPTRx (BIIB080) reduced soluble tau protein in cerebrospinal fluid (CSF) in a dose-dependent and sustained manner in patients with early-st
Mar 28, 2023 07:05 am ET
Ionis to present at upcoming investor conferences
CARLSBAD, Calif., March 28, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced its participation in fireside chats at the following investor conferences:
Mar 27, 2023 02:00 am ET
Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN
Eplontersen met co-primary endpoints demonstrating sustained reduction in TTR and benefits in neuropathy and quality of life through 66 weeks35 and 66-week data to be presented at the American Academy of Neurology (AAN) Annual Meeting in AprilCARLSBAD, Calif., March 27, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN), a debilitating and potentially fa
Mar 22, 2023 11:01 pm ET
Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS
If approved, tofersen will be the first treatment targeting a genetic cause of ALS and the next marketed Ionis-discovered antisense medicine FDA decision expected by April 25, 2023CARLSBAD, Calif., March 22, 2023 /PRNewswire/ -- Ionis (Nasdaq: IONS) today announced the outcome of the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational antisense medicine for the treatment of people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-ALS is a rare genetic form of ALS that leads
Feb 21, 2023 06:05 am ET
Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting
Phase 2 open-label study data reinforce donidalorsen's potential to be a best-in-class prophylactic treatment for patients living with hereditary angioedemaIonis is preparing to launch donidalorsen, one of its three near-term commercial opportunitiesCARLSBAD, Calif., Feb. 21, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive interim data from a Phase 2 open-label extension (OLE) study of donidalorsen, an investigational antisense medicine for the treatment of patients with hereditary angioedema (HAE). Positive interim data presented in Novem
Feb 08, 2023 06:05 am ET
Ionis to hold fourth quarter and full year 2022 financial results webcast
Webcast scheduled for Wednesday, February 22 at 11:30 a.m. Eastern Time
Feb 01, 2023 08:05 am ET
Ionis announces GSK has advanced bepirovirsen into Phase 3 development
Initiation of the Phase 3 program expands Ionis' late-stage pipeline to 7 medicines in 9 indications CARLSBAD, Calif., Feb. 1, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK has initiated two randomized, double-blind, placebo-controlled Phase 3 studies evaluating the safety and efficacy of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense medicine for the treatment of patients with chronic hepatitis B infection (CHB).
Jan 31, 2023 06:05 am ET
Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome
FCS is a rare and debilitating genetic disease often leading to significant risk of acute, potentially fatal pancreatitisIf approved, olezarsen would be the first approved treatment for FCS in the U.S.CARLSBAD, Calif., Jan. 31, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted olezarsen Fast Track designation for the treatment of familial chylomicronemia syndrome (FCS).
Jan 26, 2023 08:30 am ET
Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research
CARLSBAD, Calif., Jan. 26, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Chief Scientific Officer C. Frank Bennett, Ph.D., has been named a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research. Dr. Bennett shares this year's prize with Don W. Cleveland, Ph.D., chair and distinguished professor of cellular and molecular medicine at University of California, San Diego and Timothy M. Miller, M.D., Ph.D., vice chair of research and David Clayson professor of neurology at Washington University School of Medicin
Jan 09, 2023 09:15 am ET
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
Royalty Pharma plc (Nasdaq: RPRX) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Royalty Pharma has acquired an interest in Ionis’ royalty in Biogen’s SPINRAZA® (nusinersen) and Novartis’ pelacarsen for up to $1.125 billion,...
Jan 09, 2023 08:05 am ET
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
Royalty Pharma to acquire an interest in SPINRAZA® and pelacarsen royalties -- Ionis retains majority of royalties and all milestones from Novartis for pelacarsenRoyalty Pharma to pay Ionis $500 million upfront and up to $625 million in milestones Agreement enables Ionis to achieve commercial readiness for multiple late-stage programs and advance its innovative pipeline of genetic medicinesCARLSBAD, Calif. and NEW YORK, Jan. 9, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired an interest in
Jan 04, 2023 07:30 am ET
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
Biogen Inc. (Nasdaq: BIIB) and Alcyone Therapeutics (Alcyone) have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System, an implantable medical device intended for subcutaneous delivery of antisense...
Jan 04, 2023 06:05 am ET
Ionis to present at 41st Annual J.P. Morgan Healthcare conference
CARLSBAD, Calif., Jan. 4, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview and participate in a Q&A session at the 41st Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT (12:45 p.m. ET) on Wednesday, January 11, 2023.
Dec 05, 2022 06:30 am ET
Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
SOD1-ALS affects approximately 2% of people living with ALS worldwide1If approved, tofersen would be the world's first treatment to target a genetic cause of ALSEMA acceptance follows FDA's acceptance of tofersen NDA earlier this yearCARLSBAD, Calif., Dec. 5, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for review of tofersen, an investigational medicine for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). SOD1-ALS is a prog
Nov 14, 2022 05:05 am ET
Ionis partners with Metagenomi to add gene editing to its broad technology platform
Collaboration with a leader in gene editing systems is Ionis' latest move to expand and diversify its technology CRISPR-Cas gene editing is a natural extension of Ionis' innovative approach to delivering potentially transformative therapies Ionis to hold webcast Nov. 14 at 8 a.m. Eastern TimeCARLSBAD, Calif. and EMERYVILLE, Calif., Nov. 14, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Metagenomi today announced that the companies have entered a collaboration that will leverage Ionis' extensive expertise in RNA-targeted therapeutics and Metagenomi's versatile next-gener
Nov 13, 2022 12:01 pm ET
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
- Interim results show sustained reduction in hereditary angioedema attacks and no new safety signals in patients treated for one year
Nov 10, 2022 06:05 am ET
Ionis to present at upcoming investor conferences
CARLSBAD, Calif., Nov. 10, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
Nov 09, 2022 06:00 am ET
Ionis reports third quarter financial results
Advanced key priorities: initiated manufacturing infrastructure project to support growth
Nov 08, 2022 09:57 am ET
Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
GSK plans to advance bepirovirsen into Phase 3 development program in 1H 2023 CARLSBAD, Calif., Nov. 8, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that GSK presented positive end of study data from the Phase 2b B-Clear study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense oligonucleotide treatment for patients with chronic hepatitis B virus (CHB). The results showed that treatment with bepirovirsen resulted in sustained clearance of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA for 24 weeks after end of bepirovir
Nov 07, 2022 06:05 am ET
Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022
– IONIS-FB-LRx achieved a 44% mean reduction in proteinuria in patients treated for 6 months
Nov 04, 2022 07:05 am ET
Ionis announces positive results from fesomersen development program
- Positive Phase 2b data from RE-THINC ESRD study of fesomersen in patients on hemodialysis presented at Kidney Week 2022
Oct 26, 2022 07:05 am ET
Ionis to hold third quarter 2022 financial results webcast
CARLSBAD, Calif., Oct. 26, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced a live webcast on Wednesday, November 9th at 11:30 a.m. Eastern Time to discuss its financial results for the third quarter of 2022.
Oct 12, 2022 07:05 am ET
Ionis announces plan for new manufacturing facility in Oceanside, Calif.
Larger facility will significantly increase Ionis' development chemistry and manufacturing capabilities Sudberry Properties will build the facility and lease to Ionis for 20-plus years; Ionis retains option to renew and right of first offer to purchase the propertyCARLSBAD, Calif., Oct. 12, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into an agreement with Sudberry Properties to develop and lease a new development chemistry and manufacturing site in Oceanside, Calif. Sudberry will develop and construct the shell for the approximately 21
Sep 27, 2022 08:15 am ET
Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures
5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities...
Sep 23, 2022 02:25 am ET
Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
ION449 (AZD8233) met primary endpoint in Phase 2b SOLANO study for patients with hypercholesterolemiaION449 will not advance into Phase 3 development based on pre-specified criteriaCARLSBAD, Calif., Sept. 23, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that topline results from the Phase 2b SOLANO study in patients with hypercholesterolemia demonstrated that 60mg of ION449 (AZD8233) administered monthly achieved a statistically significant 62.3% (p<0.001) reduction in low-density lipoprotein cholesterol (LDL-C) levels after 28 weeks compared to placebo,
Sep 20, 2022 08:30 am ET
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing
Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae’s Ciitizen platform were utilized as natural history data to support the submission of Praxis’ Investigational...
Sep 07, 2022 02:30 am ET
Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis
Ionis and AstraZeneca's eplontersen demonstrated a statistically significant and clinically meaningful change from baseline for co-primary and secondary endpoints at 35 weeks compared to the external placebo groupEplontersen achieved an 81.2% reduction in the co-primary endpoint of serum transthyretin (TTR) concentration from baseline, demonstrating reduced TTR protein productionEplontersen demonstrated a favorable safety and tolerability profileCARLSBAD, Calif., Sept. 7, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a planned 35-week i
Aug 30, 2022 07:05 am ET
Ionis to present at upcoming investor conferences
CARLSBAD, Calif., Aug. 30, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
Aug 09, 2022 07:00 am ET
Ionis reports second quarter financial results and recent business achievements
Reported positive eplontersen ATTRv-PN data, on track to file NDA in H2:22
Jul 28, 2022 07:05 am ET
Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment
Phase 2b RE-THINC ESRD study of fesomersen met its primary endpoint in patients with end-stage renal disease on hemodialysisFesomersen demonstrated substantial and statistically significant reductions in Factor XI activity levelsFesomersen, a novel Factor XI antisense inhibitor designed to prevent thrombosis, was safe and well-tolerated in the study with up to 48-week treatmentCARLSBAD, Calif., July 28, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced positive topline results of the Phase 2b RE-THINC ESRD study of fesomersen, formerly IONIS-FXI-LRx, in patient
Jul 27, 2022 07:05 am ET
Ionis to hold second quarter 2022 financial results webcast
Webcast scheduled for Tuesday, August 9 at 11:30 a.m. Eastern Time
Jul 26, 2022 07:30 am ET
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S., it is progressive, leads to the loss of everyday functions and is uniformly fatal If approved, tofersen would be the first treatment to target a genetic cause of ALS12-month data included in the filing show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength, and quality of life; tofersen also led to robust and sustained reductions in neurofilament, a marker of neurodegenerationCARLSBAD, Calif., July 26, 2022 /PRNewswire/ -- Ionis Pharmaceuti
Jul 20, 2022 07:05 am ET
Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
Pelacarsen is a potentially first-in-class treatment specifically targeting elevated lipoprotein(a) (Lp(a)), an independent, inherited and causal risk factor for cardiovascular disease There are currently no approved pharmacological therapies to effectively lower Lp(a), which cannot be effectively addressed by diet and other lifestyle changes Topline results expected 2025CARLSBAD, Calif., July 20, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Novartis has completed patient enrollment of the pivotal Phase 3 Lp(a) HORIZON cardiovascular outcomes study of
Jul 13, 2022 07:05 am ET
Ionis to participate in virtual fireside chat at H.C. Wainwright 1st Annual Hereditary Angioedema Conference
CARLSBAD, Calif., July 13, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a virtual fireside chat at the H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference on Wednesday, July 20, 2022.
Jul 11, 2022 07:05 am ET
Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
- Positive data from a Phase 2 study of IONIS-FB-LRx support further development for treatment of patients with IgA nephropathy
Jun 25, 2022 09:05 am ET
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
- Interim analysis of B-Clear clinical study of bepirovirsen demonstrated end-of-treatment virologic response (VR) in patients with chronic hepatitis B
Jun 21, 2022 02:00 am ET
Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
- Eplontersen showed statistically significant and clinically meaningful improvements in mNIS+7 and Norfolk QoL-DN
Jun 13, 2022 07:05 am ET
Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
CARLSBAD, Calif., June 13, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation and rare pediatric disease designation to ION582, an investigational antisense medicine for the treatment of Angelman syndrome, a rare neurogenetic disorder caused by the loss of function of the maternally inherited Ubiquitin Protein Ligase E3A (UBE3A) gene. ION582 targets UBE3A.
Jun 03, 2022 05:20 am ET
Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
Twelve-month data show that earlier initiation of tofersen slowed decline across measures of clinical and respiratory function, strength and quality of lifeTofersen also led to robust and sustained reductions in neurofilament, a marker of neurodegenerationSOD1-ALS is a rare, progressive and fatal genetic form of the disease leading to loss of everyday functions and affecting approximately 2% of people with ALSCARLSBAD, Calif., June 3, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Biogen today announced results from the Phase 3 VALOR study and its open-label extensio
May 12, 2022 07:05 am ET
Ionis to present at RBC Capital Markets Global Healthcare Conference
CARLSBAD, Calif., May 12, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022.
May 04, 2022 07:00 am ET
Ionis reports first quarter financial results and recent business achievements
On track to achieve 2022 financial guidance
May 02, 2022 07:05 am ET
Ionis to host 2022 virtual Annual Meeting of Stockholders
CARLSBAD, Calif., May 2, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2022 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 2, 2022.
Apr 20, 2022 07:05 am ET
Ionis to hold first quarter 2022 financial results webcast
Webcast scheduled for Wednesday, May 4 at 11:30 a.m. Eastern Time
Apr 04, 2022 12:15 am ET
Ionis announces positive data for ETESIAN Phase 2b study of antisense medicine targeting PCSK9 at 2022 American College of Cardiology Scientific Session
- ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints; ION449 was generally well tolerated
Mar 28, 2022 07:30 am ET
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis (ALS), did not show clinical benefit; clinical program will be discontinued Biogen and Ionis remain committed to their decade-long pursuit of advancing ALS research and developing therapies for all forms of this progressive and fatal neurodegenerative disease CAMBRIDGE, Mass. and CARLSBAD, Calif., March 28, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx), an inve
Mar 28, 2022 07:30 am ET
Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced topline results from the Phase 1 study of BIIB078 (IONIS-C9Rx), an investigational antisense oligonucleotide (ASO) for people with C9orf72-associated...
Mar 21, 2022 07:05 am ET
Ionis to present at upcoming investor conferences
CARLSBAD, Calif., March 21, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present at the following investor conferences:
Mar 16, 2022 07:16 pm ET
Ionis announces publication of positive Phase 2 data for donidalorsen in New England Journal of Medicine
– Treatment with donidalorsen in Phase 2 study significantly reduced angioedema attacks by 90% and provided improvement in quality of life
Mar 07, 2022 06:05 am ET
Ionis calls for applications for Janice Wiesman Young Investigator Grant Program
CARLSBAD, Calif., March 7, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced it is now accepting applications for the Janice Wiesman Young Investigator Grant Program, which honors Janice Wiesman, M.D. (1958-2020), a leading global expert on the neurological impact of amyloidosis. The program awards $50,000 annually for up to two years to U.S.-based researchers whose work advances the understanding of transthyretin amyloidosis (ATTR). The deadline for applications is April 4, 2022.
Mar 01, 2022 06:05 am ET
Ionis to present at the Cowen Annual Health Care Conference
CARLSBAD, Calif., March 1, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a panel discussion on orphan neurological disease therapeutics at the virtual Cowen 42nd Annual Health Care Conference at 9:10 a.m. ET on Monday, March 7, 2022.
Feb 24, 2022 06:00 am ET
Ionis reports fourth quarter and full year 2021 financial results and recent business achievements
CARLSBAD, Calif., Feb. 24, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the fourth quarter and full year ended December 31, 2021, and recent business achievements.
Feb 10, 2022 06:05 am ET
Jan 31, 2022 06:05 am ET
Pfizer and Ionis announce discontinuation of vupanorsen clinical development program
NEW YORK and CARLSBAD, Calif., Jan. 31, 2022 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the discontinuation of the Pfizer-led clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG).
Jan 19, 2022 06:05 am ET
Ionis strengthens leadership team with appointments of Joseph Baroldi as chief business officer and Eric Bastings, M.D., as vice president, development strategy
CARLSBAD, Calif., Jan. 19, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced two appointments that strengthen its leadership team and further position it to become a leading, fully integrated biotechnology company. Joseph T. Baroldi will assume the role of executive vice president and chief business officer, effective Jan. 31, 2022. He will serve as a member of Ionis' executive leadership team and report to Brett P. Monia, Ph.D., Ionis' chief executive officer. In his role, Mr. Baroldi will provide strategic guidance for and lead Ionis' business development and
Jan 17, 2022 11:05 pm ET
Ionis' partner to evaluate tominersen for Huntington's disease in new Phase 2 trial
CARLSBAD, Calif., Jan. 18, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that its partner, Roche, is designing a new Phase 2 trial to evaluate tominersen in Huntington's disease (HD). After halting dosing in the Phase 3 GENERATION HD1 study, exploratory post-hoc analyses suggest tominersen may benefit younger adult patients with lower disease burden. These results require confirmation in a randomized, placebo-controlled study.
Jan 05, 2022 06:05 am ET
Ionis to present at 40th Annual J.P. Morgan Healthcare conference
CARLSBAD, Calif., Jan. 5, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the virtual 40th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. ET on Wednesday, January 12, 2022.
Jan 04, 2022 07:34 am ET
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306. The...
Jan 04, 2022 06:30 am ET
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
CAMBRIDGE, Mass. and CARLSBAD, Calif., Jan. 4, 2022 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306. The companies have a broad strategic collaboration to develop novel therapies to treat neurological disorders. BIIB115 is an investigational antisense oligonucleotide (ASO) in development for spinal muscular atrophy (SMA) that may have the potential to help address additional unmet needs of p
Dec 29, 2021 01:00 am ET
Ionis and AstraZeneca close deal to develop and commercialize eplontersen
CARLSBAD, Calif., Dec. 29, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapies, today announced the closing of the collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis (ATTR), following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).
Dec 07, 2021 01:00 am ET
Ionis and AstraZeneca to develop and commercialize eplontersen
CARLSBAD, Calif., Dec. 7, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has entered into a strategic collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis (ATTR).
Dec 02, 2021 02:03 pm ET
Ionis to hold virtual investor day event
CARLSBAD, Calif., Dec. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a virtual investor day on Thursday, December 9th at 11:00 a.m. Eastern Time. The company will provide an overview of its strategy, plans, and progress to bring its most advanced programs to market and achieve commercial success as well as highlight key technology advances. The webcast is expected to last approximately 2.5 hours.
Nov 24, 2021 05:30 am ET
Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen
CARLSBAD, Calif., Nov. 24, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Pfizer has provided an update on the Phase 2b study of vupanorsen, formerly IONIS-ANGPTL3-LRx. Vupanorsen is an investigational antisense therapy being developed for indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). In the dose-ranging study in subjects with elevated non-HDL-C and triglycerides (TG), the study met its primary endpoint, achieving a statistically significant reduction in non-HDL-C at all doses tested at 24 weeks, compared to pl
Nov 18, 2021 12:30 pm ET
Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema
CARLSBAD, Calif., Nov. 18, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today initiation of OASIS-HAE, the registrational study in the donidalorsen (formerly IONIS-PKK-LRx) Phase 3 clinical program. Donidalorsen is an investigational antisense medicine designed to reduce the production of prekallikrein, which plays a key role in the activation of inflammatory mediators associated with acute attacks of hereditary angioedema (HAE). Donidalorsen uses Ionis' LIgand-Conjugated Antisense, or LICA, technology.
Nov 12, 2021 06:05 am ET
Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021
CARLSBAD, Calif., Nov. 12, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today the upcoming presentations of clinical and non-clinical data from its cardiovascular pipeline, including several of its investigational antisense medicines for cardiovascular disease, at the American Heart Association (AHA) Scientific Sessions, to be held virtually Nov. 13-15, 2021.
Nov 09, 2021 06:05 am ET
Ionis to present at upcoming virtual investor conferences
CARLSBAD, Calif., Nov. 9, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in virtual fireside chats at the following virtual investor conferences:
Nov 07, 2021 06:05 am ET
Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting
CARLSBAD, Calif., Nov. 7, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today that positive results from the Phase 2 study of its investigational antisense medicine, donidalorsen (formerly IONIS-PKK-LRx), will be presented at the American College of Asthma, Allergy & Immunology (ACAAI) Annual Scientific Meeting in New Orleans and via livestream, November 4-8. The Phase 2 study results support the clinical profile of donidalorsen as a potential, best-in-class prophylactic treatment for patients with hereditary angioed
Nov 03, 2021 07:00 am ET
Ionis reports third quarter 2021 financial results and recent business achievements
CARLSBAD, Calif., Nov. 3, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the three and nine months ended September 30, 2021 and recent business achievements.
Nov 02, 2021 07:05 am ET
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
CARLSBAD, Calif., Nov. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today the initiation of CORE, the second Phase 3 clinical study of olezarsen, formerly known as IONIS-APOCIII-LRx. The CORE study is evaluating olezarsen in people with severe hypertriglyceridemia (triglyceride levels ≥ 500 mg/dL). Severe hypertriglyceridemia is a life-threatening condition associated with high levels of apoC-III and chylomicronemia, which lead to higher rates of acute pancreatitis, higher risk of cardiovascular disease, and has a high mo
Oct 20, 2021 07:05 am ET
Ionis to hold third quarter 2021 financial results webcast
CARLSBAD, Calif., Oct. 20, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 3rd at 11:30 a.m. Eastern Time to discuss its third quarter 2021 financial results and report on pipeline and business progress.
Oct 17, 2021 04:20 pm ET
Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
CARLSBAD, Calif., Oct. 17, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) partner Biogen today announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense medicine being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). While tofersen did not meet the primary endpoint of change from baseline to week 28 in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), trends favoring tofersen were seen across multiple secondary and exploratory me
Oct 14, 2021 04:06 pm ET
Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
Biogen Inc. (Nasdaq: BIIB) today announced topline results from its pivotal Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense oligonucleotide (ASO) drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic...
Sep 15, 2021 07:30 am ET
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
Biogen Inc. (Nasdaq: BIIB) today announced plans to initiate a global Phase 3b clinical study, ASCEND. The ASCEND study is designed to evaluate the clinical outcomes and assess the safety of a higher dose of nusinersen* in children, teens and...
Sep 03, 2021 07:05 am ET
Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting
CARLSBAD, Calif., Sept. 3, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today it will present 14 posters and two symposiums highlighting new scientific insights from its ATTR amyloidosis portfolio at the 3rd European ATTR Amyloidosis (EU-ATTR) meeting for Patients and Doctors on September 6-8, 2021. The posters and symposiums will include several presentations about Ionis' ATTR medicines, including its investigational antisense medicine, eplontersen, which is currently being evaluated in two phase 3 trials to potentially tre
Sep 02, 2021 07:05 am ET
Ionis to present at upcoming virtual investor conferences
CARLSBAD, Calif., Sept. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a company overview at the following virtual investor conferences:
Aug 04, 2021 07:00 am ET
Ionis reports second quarter 2021 financial results and recent business achievements
CARLSBAD, Calif., Aug. 4, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the second quarter of 2021 and recent business achievements.
Aug 02, 2021 09:30 am ET
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
CARLSBAD, Calif., Aug. 2, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis (NYSE: NVS) for exclusive worldwide development and commercialization, continues to advance in the clinic as the potential first-in-class treatment for lipoprotein(a) or Lp(a)-driven cardiovascular disease. The Novartis pivotal Phase 3 cardiovascular outcomes study of pelacarsen, Lp(a) HORIZON (NCT04023552), has reached 50% enrollment with a target goal of 7,680 trial participants.
Jul 29, 2021 07:05 am ET
Ionis completes enrollment in pivotal NEURO-TTRansform study of eplontersen
CARLSBAD, Calif., July 29, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced it has completed enrollment of NEURO-TTRansform, the company's Phase 3 study of eplontersen, formerly AKCEA-TTR-LRx, for people with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN). The company has exceeded the enrollment target in NEURO-TTRansform and expects to register more than 160 patients in the study.
Jul 26, 2021 04:35 pm ET
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
CAMBRIDGE, Mass. and CARLSBAD, Calif., July 26, 2021 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that topline data from a Phase 1b placebo-controlled, multiple ascending dose clinical study showed that BIIB080/IONIS-MAPTRx met its primary objective of safety and tolerability in patients with mild Alzheimer's disease. The study demonstrated robust time and dose dependent lowering of tau protein in cerebrospinal fluid (CSF) over the three-month treatment period and sustained reductions during the six-month post-treatment period.
Jul 21, 2021 07:05 am ET
Ionis to hold second quarter 2021 financial results webcast
CARLSBAD, Calif., July 21, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 4th at 11:30 a.m. Eastern Time to discuss its second quarter 2021 financial results and report on pipeline and business progress.
Jul 13, 2021 06:59 am ET
Ionis enters exclusive licensing agreement with Bicycle Therapeutics aimed at further advancing LICA technology
CARLSBAD, Calif., July 13, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics plc (NASDAQ: BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense (LICA) medicines. The agreement provides Ionis exclusive access to Bicycle's proprietary macrocyclic peptides, referred to as Bicycles, to design LICAs that target transferrin receptor 1 for use with oligonucleotides. This LICA strategy has demonstrated both the improved delivery of antisense medicines
Jun 14, 2021 04:05 pm ET
Ionis' Chief Scientific Officer C. Frank Bennett, Ph.D., receives Gabbay Award in Biotechnology and Medicine
CARLSBAD, Calif., June 14, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Executive Vice President and Chief Scientific Officer C. Frank Bennett, Ph.D., is a co-recipient of the 23rd Jacob and Louise Gabbay Award in Biotechnology and Medicine for his innovative work on antisense therapy. Established in 1998, the Gabbay Award recognizes scientists in academia, medicine or industry whose work has had outstanding scientific content and significant practical consequences in the biomedical sciences. The award, administered by the Rosenstiel Basic Medical Scie
Jun 10, 2021 06:05 pm ET
Ionis' antisense therapies in ATTR amyloidosis to be featured at 2021 PNS Annual Meeting
CARLSBAD, Calif., June 10, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, today announced that multiple presentations highlighting advances in its ATTR amyloidosis programs will be featured during the 2021 Peripheral Nerve Society (PNS) Annual Meeting to be held virtually on June 12-13, and 25-27, 2021. Ionis' participation highlights the advancements it's made in developing novel antisense therapies for ATTR and underscores Ionis' commitment to this patient community.
Jun 10, 2021 07:30 am ET
New Data at Cure SMA 2021 Highlight the Long-Term Efficacy of SPINRAZA® (nusinersen) and Biogen’s Commitment to Innovation in SMA Therapy
Biogen Inc. (Nasdaq: BIIB) today announced new research supporting the continued development of an investigational higher dose of SPINRAZA® (nusinersen) and additional data reinforcing the strength of SPINRAZA’s clinical profile in improving the...
Apr 19, 2021 07:30 am ET
Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
Biogen Inc. (Nasdaq: BIIB) today announced new data from the SPINRAZA® (nusinersen) clinical development program aimed at optimizing outcomes for people with spinal muscular atrophy (SMA) and advancing understanding of the disease. These data are...
Mar 08, 2021 08:05 am ET
TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S....
Feb 24, 2021 06:00 am ET
Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
CARLSBAD, Calif., Feb. 24, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the fourth quarter of 2020 and recent business highlights.
Feb 19, 2021 06:05 am ET
Ionis to present at upcoming investor conferences
CARLSBAD, Calif., Feb. 19, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that management will participate in a virtual fireside chat at the following investor conferences:
Feb 11, 2021 06:05 am ET
Ionis to hold 2020 financial results webcast
CARLSBAD, Calif., Feb. 11, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, February 24th at 9:00 a.m. Eastern Time to discuss its 2020 financial results and report on pipeline and business progress.
Jan 08, 2021 07:30 am ET
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
Biogen Inc. (Nasdaq: BIIB) today announced that the first patient has been treated in the global clinical study, RESPOND. The Phase 4 study will examine the clinical benefit and assess the safety of SPINRAZA® (nusinersen) in infants and children...
Jan 07, 2021 04:30 pm ET
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
CARLSBAD, Calif., Jan. 7, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the appointment of Eugene Schneider, M.D., as executive vice president and chief clinical development officer. In this role, Dr. Schneider will oversee clinical development of novel antisense medicines across all of Ionis' therapeutic franchises. He will report to Richard S. Geary, Ph.D., Ionis' executive vice president and chief development officer, and serve on the company's executive team.
Jan 05, 2021 06:05 am ET
Ionis to present at 39th Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif., Jan. 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the virtual 39th Annual J.P. Morgan Healthcare Conference at 3:40 p.m. ET on Tuesday, January 12, 2021.
Dec 17, 2020 05:30 pm ET
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
CARLSBAD, Calif., Dec. 17, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that its founder and executive chairman Stanley T. Crooke, M.D., Ph.D., will retire from Ionis and its board of directors effective June 2021. Dr. Crooke is stepping down so that he may focus on his scientific interests and the nonprofit organization he founded, the n-Lorem Foundation. Dr. Crooke will continue to serve as a scientific advisor to Ionis including providing advice regarding Ionis' research and development programs and guiding the c
Dec 08, 2020 08:15 pm ET
Ionis highlights achievements, commercial strategy and technology advancements at Investor Day
CARLSBAD, Calif., Dec. 8, 2020 /PRNewswire/ -- At its Investor Day yesterday, Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) highlighted the company's significant achievements in 2020 and outlined its strategy to realize the substantial opportunity of its pipeline.
Dec 02, 2020 06:05 am ET
Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference
CARLSBAD, Calif., Dec. 2, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will participate in a virtual fireside chat at the BMO 2020 Growth and ESG Conference at 3:00 p.m. E.T. on Tuesday, December 8, 2020.
Dec 01, 2020 04:10 pm ET
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
CARLSBAD, Calif., Dec. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of the Phase 3 BALANCE study for AKCEA-APOCIII-LRx in adult patients with familial chylomicronemia syndrome (FCS). FCS is a debilitating genetic disease characterized by severely high plasma levels of triglycerides and a risk of unpredictable and potentially fatal acute pancreatitis. In addition to acute pancreatitis, FCS patients are at risk of chronic complications due to permanent organ damage, including chronic pancreatitis and pancreatogenic diabetes. AKCEA-APOCIII-LR
Dec 01, 2020 06:05 am ET
Ionis to hold virtual investor day event
CARLSBAD, Calif., Dec. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live investor day webcast on Monday, December 7th at 11:00 a.m. Eastern Time to provide an overview of its commercial strategy, key opportunities in its cardiovascular and neurological franchises and recent technology advances. The approximately 3-hour webcast will include presentations from Brett P. Monia, Ph.D., chief executive officer; Sam Tsimikas, M.D., senior vice president, global cardiovascular development; C. Frank Bennett, Ph.D., chief scientific officer; On
Nov 30, 2020 04:15 pm ET
Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with dyslipidemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), an important regulator of low-density lipoprotein cholesterol (LDL-C). PCSK9 is an enzyme that controls the number of LDL receptors on the surface of cells. People with genetic variations that reduce PCS
Nov 23, 2020 04:15 pm ET
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
CARLSBAD, Calif., Nov. 23, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the biopharmaceutical company AstraZeneca has licensed ION455, an investigational antisense medicine being developed as a potential treatment for nonalcoholic steatohepatitis (NASH). ION455 is the second medicine for the treatment of NASH that Ionis has partnered with AstraZeneca. The companies have also partnered on ION839 (AZD2693), which is designed to inhibit the production of patatin-like phospholipase domain-containing 3 (PNPLA3) protein, a major genetic determinant of NASH p
Nov 13, 2020 06:05 am ET
Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020
CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that new data for ION449, an investigational antisense medicine designed to reduce plasma levels of proprotein convertase subtilisin/kexin type 9, or PCSK9, were presented today at the American Heart Association (AHA) Scientific Sessions. PCSK9 is integrally involved in the regulation of LDL-cholesterol (LDL-C). Genetic studies have shown that individuals with life-long reduction of LDL-C due to reduced function of PCSK9 have substantially reduced risk of cardiovascular disease.
Nov 12, 2020 06:05 am ET
Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020
CARLSBAD, Calif., Nov. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the upcoming presentations of clinical and non-clinical data for several of its investigational antisense medicines for cardiovascular disease at the American Heart Association (AHA) Scientific Sessions 2020, to be held virtually November 13-17, 2020.
Nov 10, 2020 06:05 am ET
Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference
CARLSBAD, Calif., Nov. 10, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that accomplished Ionis scientists will highlight the company's pioneering advancements in research and drug development in antisense technology during the RNA at the Bench and Bedside II Conference, to be held virtually Nov. 11-13, 2020. Plenary session presentations will include a review of the cardiovascular Phase 3 clinical trials Lp(a) HORIZON evaluating pelacarsen and CARDIO-TTRansform evaluating AKCEA-TTR-LRx; updates on how medicines developed using Ionis' advanced LIgand-Conjug
Nov 09, 2020 06:05 am ET
Ionis to present at upcoming virtual investor conferences
CARLSBAD, Calif., Nov. 9, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following virtual investor conferences:
Nov 06, 2020 03:00 am ET
Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung Heroes
Ionis Pharmaceuticals (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, today recognize the 3rd annual Familial Chylomicronemia Syndrome (FCS) Awareness Day, a global observance held each year on the first Friday in November to build broader awareness of the challenges associated with this debilitating, ultra-rare disease. Together with members of the FCS community, Ionis and Akcea have made significant progress in efforts to help people around the world learn about FCS and the impact it has on patients, their families and caregivers.
Nov 04, 2020 06:00 am ET
Ionis reports third quarter 2020 financial results and recent business achievements
CARLSBAD, Calif., Nov. 4, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the third quarter of 2020 and recent business highlights.
Nov 03, 2020 05:00 pm ET
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs). The study, Targeting ANGPTL3 with an antisense oligonucleotide in adults with dyslipidemia (TRANSLATE-TIMI 70), will evaluate various doses of vupanorsen to inform potential future development.
Oct 30, 2020 07:00 am ET
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
BOSTON and CARLSBAD, Calif., Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary, Akcea Therapeutics, received the Prix Galien USA Award for the Best Biotechnology Product in 2020 in recognition of TEGSEDI, the first and only self-administered, subcutaneous treatment for the polyneuropathy of hereditary ATTR amyloidosis in adults. This Prix Galien award recognizes outstanding achievements in biomedicine that improve the human condition and was presented at a virtual ceremony on Thursday, Oct. 29.
Oct 22, 2020 07:05 am ET
Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
CARLSBAD, Calif., Oct. 22, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that the first patients have been dosed with ION541 (also known as BIIB105), an investigational antisense medicine being developed as a potential therapy to treat most forms of amyotrophic lateral sclerosis (ALS) regardless of family history. This is another milestone in the continuing progress of Ionis' ambitious program to develop novel treatments for ALS. Almost all cases of ALS share the pathological hallmark of TDP-43 protein aggregation in mo
Oct 21, 2020 07:05 am ET
Ionis to hold third quarter 2020 financial results webcast
CARLSBAD, Calif., Oct. 21, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 4th at 11:30 a.m. Eastern Time to discuss its third quarter 2020 financial results and report on pipeline and business progress.
Oct 15, 2020 07:05 am ET
Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
CARLSBAD, Calif., Oct. 15, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that IONIS-PKK-LRx is being evaluated in an investigator-initiated Phase 2 clinical study to determine its effectiveness in reducing the severity of respiratory complications in patients with COVID-19. The trial coordinators are Fernando G. Zampieri, M.D., Ph.D., and Alexandre Biasi Cavalcanti, M.D., Hospital do Coracao (HCor Research Institute), Sao Paulo, Brazil. The study will enroll up to 110 patients at 25 hospitals in Brazil. Ionis has p
Oct 13, 2020 12:32 pm ET
/C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./
In the news release, Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis, issued 13-Oct-2020 by Ionis Pharmaceuticals, Inc. over PR Newswire, we are advised by the company that the first paragraph, first sentence, should read "Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that data from a clinical trial of IONIS-ENAC-2.5Rx demonstrated a significant decrease in the expression of epithelial sodium channel (ENaC) in healthy subjects." rather than "Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the le
Oct 13, 2020 07:05 am ET
Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
CARLSBAD, Calif., Oct. 13, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that data from a clinical trial of IONIS-ENAC-2.5Rx demonstrated a significant decrease in the expression of epithelial sodium channel (ENaC) in subjects with cystic fibrosis (CF). The study showed a mean 55.6 percent decrease (p<0.05) in ENaC mRNA expression at the 75 mg dose in the multidose segment of the trial. The study represents the first time an antisense medicine delivered directly to the lung via a nebulizer has shown a significant red
Aug 05, 2020 07:00 am ET
Ionis reports second quarter 2020 financial results and recent business achievements
CARLSBAD, Calif., Aug. 5, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the second quarter of 2020 and recent business highlights.
Jul 22, 2020 07:05 am ET
Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast
CARLSBAD, Calif., July 22, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 5th at 11:30 a.m. Eastern Time to discuss its second quarter 2020 financial results and report on pipeline and business progress.
Jul 21, 2020 07:00 am ET
Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
BOSTON, July 21, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2020 financial results and report on pipeline and business progress.
Jul 20, 2020 07:00 am ET
Akcea Appoints New Senior Vice President, Global Medical Affairs
BOSTON, July 20, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Christophe Hotermans, M.D., Ph.D., has joined the company as senior vice president of global medical affairs where he will lead and evolve the execution of medical strategies, activities and operations worldwide in collaboration with executive management.
Jul 09, 2020 07:00 am ET
Akcea Announces Appointment of New Chief Medical Officer
BOSTON, July 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP, has joined the company as chief medical officer (CMO), effective immediately. Dr. Andrews will lead medical, clinical and regulatory functions in support of the company's two commercial-stage products TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen) and will also guide development of the multiple clinical-stage therapeutics in the pipeline. Former CMO Louis St. L. O'Dea, MB, BCh, BAO, FRCP(C), will serve as a
Jul 07, 2020 07:05 am ET
Ionis Pharmaceuticals to hold neurology franchise webcast
CARLSBAD, Calif., July 7, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, July 14th at 10:00 a.m. Eastern Time to review its neurology franchise. The approximately 90-minute webcast will include presentations from Brett P. Monia, Ph.D., chief executive officer; C. Frank Bennett, Ph.D., chief scientific officer and franchise leader for neurology; Holly Kordasiewicz, Ph.D., vice president, neurology research; and Frank Rigo, Ph.D., vice president, functional genomics and drug discovery. The agenda for the webcast will
Jun 17, 2020 07:00 am ET
Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
BOSTON, June 17, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, chief executive officer, and Kyle Jenne, chief commercial officer, will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference, which is being held virtually, on Tuesday, June 23, 2020 at 3:30 p.m. ET.
Jun 09, 2020 07:00 am ET
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
BOSTON, June 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Kia Motesharei, Ph.D., has joined the company as Senior Vice President of Business Development & Corporate Strategy. In this role Dr. Motesharei will drive business development activities at Akcea as well as continue to enhance the corporate strategy in conjunction with the Akcea leadership team.
Jun 05, 2020 07:05 am ET
Ionis Pharmaceuticals to present at upcoming virtual investor conferences
CARLSBAD, Calif., June 5, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following virtual investor conferences:
May 28, 2020 04:05 pm ET
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
CARLSBAD, Calif., May 28, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2020 virtual Annual Meeting of Stockholders and provide a general corporate update on Thursday, June 4, 2020. This event will be webcast live on the internet in place of an in-person meeting. To protect the health and safety of our stockholders, directors and employees, and in compliance with federal, state and local guidance related to COVID-19, the Company will not host an in-person meeting this year.
May 28, 2020 07:00 am ET
Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Even
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced publication of long-term data from the open-label extension (OLE) of the pivotal...
May 18, 2020 07:00 am ET
Akcea Announces Appointment of New Chief Financial Officer
BOSTON, May 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined the company as executive vice president and chief financial officer. In this role, Mr. Price will oversee financial operations at the company including managing financial strategies and activities related to clinical and regulatory functions, commercial sales, marketing, manufacturing and supply chain.
May 07, 2020 07:00 am ET
Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
BOSTON, May 7, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president and chief human resources officer. In these roles, Ms. Poulson will be a part of the executive leadership team and provide proactive, strategic leadership and consultation across all company functions. She will also develop and drive initiatives to continue to build company culture and to support the company's business strategy.
May 06, 2020 07:00 am ET
Ionis reports first quarter 2020 financial results and recent business achievements
CARLSBAD, Calif., May 6, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2020 and recent business highlights.
May 05, 2020 04:05 pm ET
Akcea Reports Financial Results and Highlights for First Quarter 2020
BOSTON, May 5, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2020. The company reported a net loss for the first quarter ended March 31, 2020 on a GAAP basis of $43 million and on a non-GAAP basis of $36 million. Akcea had $421 million of cash, cash equivalents and short-term investments as of March 31, 2020.
May 01, 2020 07:05 am ET
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
CARLSBAD, Calif., May 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2020 Virtual Annual Meeting of Stockholders and provide a general corporate update on Thursday, June 4, 2020. In consideration of the health and well-being of our stockholders, directors and employees, and in compliance with federal, state and local guidance with regards to the COVID-19 pandemic, the Annual Meeting will be held in a virtual meeting format only, via live webcast on the internet, with no physical in-person meeting this year.
Apr 22, 2020 07:05 am ET
Ionis Pharmaceuticals to hold first quarter 2020 financial results webcast
CARLSBAD, Calif., April 22, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, May 6th at 11:30 a.m. Eastern Time to discuss its first quarter 2020 financial results and report on pipeline and business progress.
Apr 21, 2020 07:00 am ET
Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, May 5 at 4:30 p.m. Eastern Time to discuss its first quarter 2020 financial results and...
Apr 20, 2020 07:05 am ET
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
CARLSBAD, Calif., April 20, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, today announced that its partner Roche, also known as Genentech in the United States, has completed enrollment for GENERATION HD1, a global Phase 3 study evaluating the efficacy and safety of tominersen (previously IONIS-HTTRx or RG6042), an investigational antisense therapy for people living with Huntington's disease (HD).
Apr 08, 2020 07:05 am ET
Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs
CARLSBAD, Calif., April 8, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, today announced that it has established a $25,000 scholarship to help ALS patients in the greater San Diego area participate in a range of physical and mental wellness programs that offer an integrative approach for overcoming the challenges of disability. The Ionis Hope Scholarship will enable ALS patients to participate in group classes, massage therapy, meditation and functional movement therapy, offered by Adapt Functional Movement Center, located in Carlsbad, Calif. Duri
Apr 07, 2020 07:05 am ET
Ionis Pharmaceuticals to present at upcoming investor conferences
CARLSBAD, Calif., April 7, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:
Mar 11, 2020 07:00 am ET
Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Lisa Johnson-Pratt, M.D., has joined the company as senior vice president of new product strategy. In this role, Dr....
Feb 28, 2020 07:00 am ET
Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the company’s support for Rare Disease Day 2020 and the effort to help more people learn about the impact of rare diseases on...
Feb 26, 2020 07:00 am ET
Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, Interim CEO,...
Feb 13, 2020 07:00 am ET
Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Amber Salzman, Ph.D., to the Company’s Board of Directors, expanding the board to 11 members. Dr. Salzman has...
Jan 28, 2020 04:05 pm ET
Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive topline results from the Phase 2 study of AKCEA-ANGPTL3-LRx in patients...
Jan 10, 2020 07:00 am ET
Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the initiation of the CARDIO-TTRansform Phase 3 cardiovascular outcomes study for...
Jan 02, 2020 08:00 am ET
New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile Global Lp(a)HORIZON Phase 3 cardiovascular outcomes study underway BOSTON and CARLSBAD, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) --...
Dec 18, 2019 10:03 pm ET
Akcea Retains Rights to AKCEA-APOCIII-LRx
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that, following a strategic portfolio decision by Novartis not to exercise its...
Dec 04, 2019 07:00 am ET
Akcea Announces Appointment of New Chief Operating Officer
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the company as chief operating officer. In this role, Mr. Howarth will oversee a broad range of...
Nov 25, 2019 07:00 am ET
Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced initiation of the NEURO-TTRansform Phase 3 clinical trial for AKCEA-TTR-LRx in...
Nov 19, 2019 04:05 pm ET
Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the closing of the exclusive licensing agreement with Pfizer Inc. (NYSE:PFE) for...
Nov 12, 2019 06:05 am ET
Ionis Pharmaceuticals to present at upcoming investor conferences
CARLSBAD, Calif., Nov. 12, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences:
Nov 06, 2019 06:00 am ET
Ionis provides third quarter financial results and improved 2019 guidance
CARLSBAD, Calif., Nov. 6, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the third quarter and year-to-date 2019 and recent business highlights.
Oct 28, 2019 07:05 am ET
Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference
CARLSBAD, Calif., Oct. 28, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that Ionis scientists will give presentations highlighting antisense medicines for neurological diseases and two LIgand Conjugated Antisense (LICA) medicines, IONIS-FXI-LRx and IONIS-TMPRSS6-LRx at the DIA/FDA Oligonucleotide-Based Therapeutics Conference in North Bethesda, Maryland, Oct. 28-30, 2019. The presentations by Ionis will showcase the company's expertise in the field of antisense medicines and the potential of these medicines to trans
Oct 23, 2019 07:05 am ET
Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences
CARLSBAD, Calif., Oct. 23, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapeutics, announced today that Ionis' Chairman and Chief Executive Officer, Stanley T. Crooke, M.D., Ph.D., is one of two scientists to be awarded the 2019 Massry Prize. Dr. Crooke, who founded Ionis 30 years ago to create a radically different drug discovery platform, was recognized by the Massry Foundation for his pioneering work to establish an entirely new chemical class of medicines, antisense oligonucleotides. Ionis' antisense technology has created the life-changi
Oct 22, 2019 07:05 am ET
Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast
CARLSBAD, Calif., Oct. 22, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2019 financial results and report on pipeline and business progress.
Oct 22, 2019 07:00 am ET
Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, November 5th at 4:30 p.m. Eastern Time to discuss its third quarter 2019 financial results and report...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.